Non-small cell lung cancer · line 2 · Docetaxel + Ramucirumab (REVEL) — 2L+ NSCLC post-platinum / post-ICI
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-DOCETAXEL-RAMUCIRUMAB |
| ID | IND-NSCLC-2L-PD-L1-POST-IO-DOCETAXEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-LUMELUNG1-RECK-2014 SRC-NCCN-NSCLC-2025 SRC-REVEL-GARON-2014 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L cytotoxic for driver-negative metastatic NSCLC post-1L chemo+ICI failure. Driver-positive (EGFR, ALK, ROS1, KRAS G12C, MET, BRAF, RET, NTRK, HER2) excluded — those receive next-line targeted TKI. This Indication is closely related to existing IND-NSCLC-2L-DOCETAXEL- RAMUCIRUMAB but is the canonical "default branch" target of the ALGO-NSCLC-METASTATIC-2L decision tree.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L